Management of Asymptomatic Mycoplasma hominis Colonization in Adult Males
No treatment is recommended for asymptomatic adult males incidentally found to be colonized with Mycoplasma hominis.
Rationale for Non-Treatment
The strongest guideline evidence explicitly advises against routine testing and treatment of asymptomatic individuals for M. hominis colonization 1. This position is based on several key principles:
- Asymptomatic carriage is common and benign in the general population, with the majority of colonized individuals never developing disease 1
- No evidence exists that detection and treatment of asymptomatic colonization provides more benefit than harm 1
- Unnecessary antimicrobial treatment drives resistance in M. hominis, other sexually transmitted pathogens, and the general microbiota 1
When M. hominis Testing Should Be Considered
The EAU 2024 guidelines recommend targeted testing for M. hominis only in specific clinical contexts 2:
- Symptomatic chronic bacterial prostatitis with risk factors for atypical infections, using nucleic acid amplification testing (NAAT) 2
- Symptomatic urethritis after excluding N. gonorrhoeae, C. trachomatis, M. genitalium, and T. vaginalis 1
- Extragenital infections in immunocompromised patients (hypogammaglobulinemia, post-transplant, post-neurosurgery) presenting with culture-negative persistent infections, particularly with arthritis or abscess formation 3, 4
Important Caveats
The Infertility Question
One study suggested asymptomatic M. hominis infection may impair semen parameters and fertility, with improvement after antibiotic treatment 5. However, this single 2017 study contradicts the 2018 European STI Guidelines Editorial Board position statement 1, which represents consensus expert opinion and should take precedence in routine practice. For men actively seeking fertility evaluation with abnormal semen parameters, consider targeted testing and treatment only in that specific context 5.
Risk of Invasive Disease
M. hominis can cause serious extragenital infections including:
- Central nervous system infections (meningitis, brain abscess) in post-traumatic or post-surgical patients 3
- Bacteremia and septic arthritis in immunocompromised hosts 4
- Necrotizing pneumonia even in immunocompetent individuals 6
However, these complications arise from invasive disease, not asymptomatic colonization. Asymptomatic colonization does not predict or necessitate prophylactic treatment to prevent these rare complications 1.
If Treatment Were Indicated (Symptomatic Disease Only)
When M. hominis causes documented symptomatic infection, the preferred antimicrobial agents are 3, 6:
- Fluoroquinolones (levofloxacin or moxifloxacin): Most effective first-line option
- Tetracyclines (doxycycline): Alternative agent
- Clindamycin: Second-line alternative 7, 8
M. hominis is naturally resistant to all beta-lactams, macrolides (including erythromycin and azithromycin), aminoglycosides, and sulfonamides due to its lack of a cell wall 7, 8, 6.
Common Pitfall to Avoid
Do not treat based solely on positive multiplex PCR panel results in asymptomatic individuals. The commercialization of multiplex PCR assays that detect M. hominis alongside traditional STI pathogens has led to overdiagnosis and overtreatment 1. A positive test in an asymptomatic male represents colonization, not infection requiring treatment.